Cyndi Green, PhD, MBA, currently has responsibility for partnering and diligence for vaccines and anti-infectives at Pfizer in Manhattan. Dr. Green’s deal portfolio includes the acquisition of GSK and Baxter vaccines, the out-licensing of sutezolid to Sequella, the formation of ViiV JV with GSK, and formation of new company RGo Biosciences (previously in The Pfizer Incubator, La Jolla). In 2016, Dr. Green led the diligence and transition service activities for the acquisition of AstraZeneca’s small molecule antibiotics portfolio of marketed, approved and pipeline products.